Recent studies have suggested that dopamine agonists (DAs), widely used in Parkinson's disease (PD) management, might increase the risk of sudden uncontrollable somnolence. Avorn et al.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback